Spyridon Fortis, MD
Pulmonary Disease · Iowa City, IANPI 1831329630
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $161 of the $188 with a category attached, or 85.5%. AbbVie accounts for 62.7% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for pulmonary disease clinicians in IA, where the typical reported total is $578.
Across 3 payments — averaging $62.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$118
- AstraZeneca$70
Across 17 payments — averaging $9965.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$62K
- GSK$57K
- AstraZeneca$49K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Travel & lodging$2714%
- Food & beverage$16186%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $118 |
| AstraZeneca | 2 | $70 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$118
How this compares
$188 in reported general payments places this provider in the 35th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 30 | $158,091 |
| Dupixent PenDupilumab | 34 | $135,265 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 199 | $130,247 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $37,216 |
| Spiriva RespimatTiotropium Bromide | 54 | $36,074 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $24,705 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $18,362 |
| DuleraMometasone/Formoterol | 43 | $16,293 |
| Advair HfaFluticasone Propion/Salmeterol | 38 | $14,297 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $13,996 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $13,234 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $9,124 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,792 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $8,420 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $6,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $70 | $51,212103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Iowa City
- Alejandro ComellasIowa City$54K
- Rolando Sanchez SanchezIowa City$12K
- Nabeel HamzehIowa City$9K
- Douglas HornickIowa City$8K
- Robert SmythIowa City$6K
- Joel KlineIowa City$5K
- Tahuanty PenaIowa City$2K
- Alan MoyIowa City$2K
- Kimberly Baker-El AbiadIowa City$831
- Bryan KrajicekCouncil Bluffs$470K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.